US 8022057
MAPK/ERK kinase inhibitors
granted A61PA61P1/04A61P1/18
Quick answer
US patent 8022057 (MAPK/ERK kinase inhibitors) held by Takeda Pharmaceutical Company Limited expires Mon Sep 15 2031 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Takeda Pharmaceutical Company Limited
- Grant date
- Tue Sep 20 2011 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Sep 15 2031 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 82
- CPC classes
- A61P, A61P1/04, A61P1/18, A61P11/00, A61P11/06